Strategies for extended serum half-life of protein therapeutics

Current Opinion in Biotechnology

Volumn 22, Issue 6, 2011, Pages 868-876

  Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HALF-LIFE OF PROTEIN; HYDRODYNAMIC VOLUMES; NEONATAL FC RECEPTORS; PHARMACEUTICAL INDUSTRY; PROTEIN DRUGS; PROTEIN THERAPEUTICS; RECYCLING PROCESS;

BIOTECHNOLOGY;

PROTEINS;

ALBINTERFERON ALPHA2B; ALEFACEPT; ALPHA2B INTERFERON; ASPARAGINASE MACROGOL; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ETANERCEPT; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INSULIN DETEMIR; INTERLEUKIN 6 ANTIBODY; JOULFERON; LEMEVIR; LEPTIN; LIRAGLUTIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGADEMASE; PEGINESATIDE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON LAMBDA; PEGLOTICASE; PEGVISOMANT; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SERUM ALBUMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALBIN;

ACROMEGALY; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANKYLOSING SPONDYLITIS; BIOTECHNOLOGY; CONJUGATION; CROHN DISEASE; DIABETES MELLITUS; DRUG BINDING SITE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENDOCYTOSIS; GOUT; HEMOPHILIA B; HEPATITIS C; HUMAN; HYDRODYNAMICS; JUVENILE RHEUMATOID ARTHRITIS; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEVERE COMBINED IMMUNODEFICIENCY;

CARBOHYDRATE METABOLISM; GLYCOSYLATION; HALF-LIFE; HUMANS; HYDRODYNAMICS; POLYETHYLENE GLYCOLS; PROTEIN ENGINEERING; PROTEINS; RECOMBINANT PROTEINS; SERUM;

EID: 82755197856     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2011.06.012     Document Type: Review

References (58)

1. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010, 28:917-924.
2. Tang L., Persky A.M., Hochhaus G., Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharmaceut Sci 2004, 93:2184-2204.
3. Tryggvason K., Wartiovaara K. How does the kidney filter plasma?. Physiology 2005, 20:96-101.
4. Haraldsson B., Sörensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. New Physiol Sci 2004, 19:7-10.
5. Wartiovaara J., öfverstedt L.G., Khoshnoodi J., Zhang J., Mäkelä E., Sandin S., Ruotsalainen V., Cheng R.H., Jalanko H., Skoglund U., Tryggvason K. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 2004, 114:1475-1483.
6. Kontermann R.E. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009, 23:93-109.
7. Roopenian D.C., Akilesh S. FcRn the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7:715-725.
8. Lao B.J., Kamei D.T. Improving therapeutic properties of protein drugs through alteration of intracellular trafficking pathways. Biotechnol Prog 2008, 24:2-7.
9. Sarkar C.S., Lowenhaupt K., Horan T., Boone T.C., Tidor B., Lauffenburger D.A. Rational cytokine design for increased lifetime and enhanced potentcy using pH-activated "histidine switching" Nat Biotechnol 2002, 20:908-913.
10. Igawa T., Ishii S., Tachibana T., Maeda A., Higuchi, Shimaoka S., Moriyama C., Watanabe T., Takubo R., Doi Y., et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010, 28:1203-1208.
11. Veronese F.M., Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008, 22:315-329.
12. Fishburn C.S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008, 97:4167-4183.
13. Melmed G.Y., Targan S.R., Yasothan U., Hanicq D., Kirkpatrick P. Certolizumab pegol. Nat Rec Drug Disov 2008, 7:641-642.
14. Jevsevar S., Junstelj M., Porekar V.G. PEGylation of therapeutic proteins. Biotechnol J 2010, 5:113-128.
15. Brocchini S., Godwin A., Balan S., Choi J., Zloh M., Shaunak S. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev 2008, 60:3-12.
16. Gaberc-Porekar V., Zore I., Podobnik B., Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Dev 2008, 11:242-250.
17. Schellenberger V., Wang C.W., Geething N.C., Spink B.J., Campbell A., To W., Scholle M.D., Yin Y., Yao Y., Bogin O., et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 2009, 27:1186-1190.
18. Geething N.C., To W., Spink B.J., Scholle M.D., Wang C.W., Yin Y., Yao Y., Schellenberger V., Cleland J.L., Stemmer W.P.C., Silverman J. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS ONE 2010, 5:e10175.
19. Solá R.J., Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 2010, 24:9-21.
20. Kiss Z., Elliott S., Jedynasty K., Tesar V., Szegedi J. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Eur J Clin Pharmacol 2010, 66:331-340.
21. Ceaglio N., Etcheverrigaray M., Conradt H.S., Grammel N., Kratje R., Oggero M. Highly glycosylated human alpha interferon: an insight into a new therapeutic candidate. J Biotechnol 2010, 146:74-83.
22. Stork R., Zettlitz K.A., Müller D., Rether M., Hanisch F.G., Kontermann R.E. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008, 283:7804-7812.
23. Müller D., Kontermann R.E. Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs 2010, 24:89-98.
24. Fares F., Ganem S., Hajouj T., Agai E. Development of a long-acting erythropoietin by fusing the carboxy-terminal peptide of human chorionic gonadotropin β-subunit to the coding sequence of human erythropoietin. Endrocrinology 2007, 148:5081-5087.
25. Fares F., Guy R., Bar-Ilan A., Felikman Y., Fima E. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin β-subunit to the coding sequence of hGH. Endocrinology 2010, 151:4410-4417.
26. Agreda-Vásquez G.P., Espinosa-Poblano I., Sánchez-Guerrero S.A., Crespo-Solís E., Cabrera-Vásquez S., López-Salmorán J., Barajas J., Peñaloza-Ramírez P., Tirado-Cárdenas N., Velázquez A. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective. J Clin Apher 2008, 23:163-167.
27. Gregoriadis G., Jain S., Papaioannou I., Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm 2005, 300:125-130.
28. Constantinou A., Epenetos A.A., Hreczuk-Hirst D., Jain S., Wright M., Chester K.A., Deonarain M.P. Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug Chem 2009, 20:924-931.
29. Zhang R., Jain S., Rowland M., Hussain N., Agarwal M., Gregoriadis G. Development and testing of solid dose formulations containing polysialic acid insulin conjugate: next generation of long-acting insulin. J Diabetes Sci Technol 2010, 4:532-539.
30. Tabrizi M.A., Tseng C.M.L., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11:81-88.
31. Keizer R.J., Huitema A.D.R., Schellens J.H.M., Beijnen J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010, 49:493-507.
32. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W.L., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010, 28:157-159.
33. Yeung Y.A., Wu X., Reyes A.E., Vernes J.M., Lein S., Lowe J., Maia M., Forrest W.F., Meng Y.G., Damico L.A., et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010, 70:3269-3277.
34. Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 2009, 20:692-699.
35. Suzuki T., Watabe A.I., Tada M., Kobayashi T., Kanayasu-Toyoda T., Kawanishi T., Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010, 184:1968-1976.
36. Chaudhury C., Brooks C.L., Carter D.C., Robinson J.M., Anderson C.L. Albumin binding to FcRn: distinct from the FcRn-Igg interaction. Biochemistry 2006, 45:4983-4990.
37. Chuang V.T.G., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002, 19:569-577.
38. Rustgi V.K. Albinterferon alf-2b, a novel fusion protein of human albumin and human interferon alf-2b, for chronic hepatitis C. Curr Med Res Opin 2009, 25:991-1002.
39. Nelson D.R., Benhamou Y., Chuang W.L., Lawitz E.J., Rodriguez-Torres M., Flisiak R., Rasenack J.W., Kryczka W., Lee C.M., Bain V.G., et al. Albinterferon alfa-2b was not inferior to PEGylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010, 139:1267-1276.
40. Schulte S. Half-life extension through albumin fusion technologies. Thromb Res 2009, 124:S6-S8.
41. Metzner H.J., Weimer T., Kronthaler U., Lang W., Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009, 102:634-644.
42. Müller D., Karle A., Meißburger B., Höfig I., Stork R., Kontermann R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007, 282:12650-12660.
43. Yazaki P.J., Kassa T., Cheung C.W., Crow D.M., Sherman M.A., Bading J.R., Anderson A.L.J., Colcher D., Raubitschek A. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 2008, 35:151-158.
44. Evans L., Hughes M., Waters J., Cameron J., Dodsworth N., Tooth D., Greenfield A., Sleep D. The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif 2010, 73:113-124.
45. Kenanova V.E., Olafsen T., Salazar F.B., Williams L.E., Knowles S., Wu A.M. Tuning the serum persistence of human serum albumin domain III: diabody fusion proteins. Protein Eng Des Sel 2010, 23:789-798.
46. Kratz F. Albumin as drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Res 2008, 132:171-183.
47. Xie D., Yao C., Wang L., Min W., Xu J., Xiao J., Huang M., Chen B., Liu B., Li X., Jiang H. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 2010, 54:191-196.
48. Sørensen A.R., Stidsen C.E., Ribel U., Nishimiura E., Sturis J., Jonassen I., Bouman S.D., Kurtzhals P., Brand C.L. Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes Obes Metab 2010, 12:665-673.
49. Dumelin C.E., Trüssel S., Buller F., Trachsel E., Bootz F., Zhang Y., Mannocci L., Beck S.C., Drumea-Mirancea M., Seeliger M.W., et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed 2008, 47:3196-3201.
50. Trüssel S., Dumelin C., Frey K., Villa A., Buller F., Neri D. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem 2009, 20:2286-2292.
51. Stork R., Müller D., Kontermann R.E. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 2007, 20:569-576.
52. Andersen J.T., Pehrson R., Tolmachev V., Bekele M.D., Abrahmsen L., Ekblad C. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain (ABD). J Biol Chem 2010, 286:5234-5241.
53. Hopp J., Hornig N., Zettlitz K.A., Schwarz A., Fuss N., Müller D., Kontermann R.E. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 2010, 23:827-834.
54. Stork R., Campigna E., Robert B., Müller D., Kontermann R.E. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009, 284:25612-25619.
55. Roovers R.C., Laeremans T., Huang L., De Taeye S., Verkleij A.E., Revets H., de Haard H.J., van Berg en Henegouwen P.M.P. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR nanobodies. Cancer Immunol Immunother 2007, 56:303-317.
56. Tijink B.M., Laeremans T., Budde M., Stigter-van Walsum M., Dreier T., de Haard H.J., Leemans C.R., van Dongen G.A. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 2008, 7:2288-2297.
57. Holt L.J., Basran A., Jones K., Chorlton J., Jespers L.S., Brewis N.D., Tomlinson I.M. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008, 21:283-288.
58. Walker A., Dunlevy G., Rycroft D., Topley P., Holt L.J., Herbert T., Davies M., Cook F., Holmes S., Jespers L., Herring C. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. Protein Eng Des Sel 2010, 23:271-278.